Advocates call on TB Alliance to make public the pretomanid licensing agreement with Mylan
Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.
On 10 June 2019, TB advocates sent an
open letter
to TB Alliance requesting that the organization make public its
recent agreement with Mylan, announced 18 April 2019.
“Full access to the terms of the agreement granting
Mylan the rights to commercialize pretomanid is critical to
our work to ensure equitable access to TB
treatments.”
The signatories requested a response by
18 June 2019.
To read the full
letter, click
here.
